Deborah L. Burnett

Deborah L. Burnett

Auto-generated profile, based on publicly available information

Deborah L. Burnett

School of Biomedical Sciences UNSW Sydney Kensington New South Wales Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2018 in Science
Verified
Journal Article
Closed access
PDF file
DBDeborah L. Burnett
Deborah L. Burnett
DLDavid B. Langley
David B. Langley
PSPeter Schofield
Peter Schofield
JHJana R. Hermes
Jana R. Hermes
TCTyani D. Chan
Tyani D. Chan
CGChristopher C. Goodnow
Christopher C. Goodnow
Autoantibody redemption through rapid mutations: Antibodies distinguish foreign epitopes from closely related self-antigens by poorly understood mechanisms. In mice, Burnett et al. found that a proportion of B cells could cross-react with similar foreign and self-antigens (see the Perspective by Kara and Nussenzweig). Challenge with self-antigen resulted in anergy (i.e., a lack of immune response), which was reversed by exposure to high-density foreign antigen. Mutations that decreased self-affinity were rapidly selected for, whereas selection for epistatic mutations that enhanced foreign reactivity took longer. Self-reactivity, rather than being an impediment to immunization, resulted in higher affinities against a foreign immunogen. Science , this issue p. 223 ; see also p. 152

26 September 2019 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
DBDeborah L. Burnett
Deborah L. Burnett
JRJoanne H. Reed
Joanne H. Reed
DCDaniel Christ
Daniel Christ
CGChristopher C. Goodnow
Christopher C. Goodnow

29 October 2021 in Immunity
Verified
Journal Article
Open access
DBDeborah L. Burnett
Deborah L. Burnett
KJKatherine J.L. Jackson
Katherine J.L. Jackson
DLDavid B. Langley
David B. Langley
AAAnupriya Aggarwal
Anupriya Aggarwal
ASAlberto Ospina Stella
Alberto Ospina Stella
CGChristopher C. Goodnow
Christopher C. Goodnow
Viral mutations are an emerging concern in reducing SARS-CoV-2 vaccination efficacy. Second-generation vaccines will need to elicit neutralizing antibodies against sites that are evolutionarily conserved across the sarbecovirus subgenus. Here, we immunized mice containing a human antibody repertoire with diverse sarbecovirus receptor-binding domains (RBDs) to identify antibodies targeting conserved sites of vulnerability. Antibodies with broad reactivity against diverse clade B RBDs targeting the conserved class 4 epitope, with recurring IGHV/IGKV pairs, were readily elicited but were non-neutralizing. However, rare class 4 antibodies binding this conserved RBD supersite showed potent neutralization of SARS-CoV-2 and all variants of concern. Structural analysis revealed that the neutralizing ability of cross-reactive antibodies was reserved only for those with an elongated CDRH3 that extends the antiparallel beta-sheet RBD core and orients the antibody light chain to obstruct ACE2-RBD interactions. These results identify a structurally defined pathway for vaccine strategies eliciting escape-resistant SARS-CoV-2 neutralizing antibodies.

8 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
RRRomain Rouet
Romain Rouet
JHJake Y. Henry
Jake Y. Henry
Matt JohansenMatt Johansen
Matt Johansen
MSMeghna Sobti
Meghna Sobti
HBHarikrishnan Balachandran
Harikrishnan Balachandran
DCDaniel Christ
Daniel Christ
Emerging variants of concern (VOCs) are threatening to limit the effectiveness of SARS-CoV-2 monoclonal antibodies and vaccines currently used in clinical practice; broadly neutralizing antibodies and strategies for their identification are therefore urgently required. Here we demonstrate that broadly neutralizing antibodies can be isolated from peripheral blood mononuclear cells of convalescent patients using SARS-CoV-2 receptor binding domains carrying epitope-specific mutations. This is exemplified by two human antibodies, GAR05, binding to epitope class 1, and GAR12, binding to a new epitope class 6 (located between class 3 and 5). Both antibodies broadly neutralize VOCs, exceeding the potency of the clinical monoclonal sotrovimab (S309) by orders of magnitude. They also provide prophylactic and therapeutic in vivo protection of female hACE2 mice against viral challenge. Our results indicate that exposure to SARS-CoV-2 induces antibodies that maintain broad neutralization against emerging VOCs using two unique strategies: either by targeting the divergent class 1 epitope in a manner resistant to VOCs (ACE2 mimicry, as illustrated by GAR05 and mAbs P2C-1F11/S2K14); or alternatively, by targeting rare and highly conserved epitopes, such as the new class 6 epitope identified here (as illustrated by GAR12). Our results provide guidance for next generation monoclonal antibody development and vaccine design.

27 August 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DBDeborah L. Burnett
Deborah L. Burnett
PSPeter Schofield
Peter Schofield
DLDavid B. Langley
David B. Langley
JJJennifer Jackson
Jennifer Jackson
KBKatherine Bourne
Katherine Bourne
DCDaniel Christ
Daniel Christ
Significance: Conformational diversity of foreign antigens and cross-reactivity with self are implicated in the failure to generate effective antibody responses against many challenging pathogens, but few studies directly address how these two factors affect antibody formation. Here we address this question from biophysical, structural, and immunological perspectives using structurally related lysozyme proteins. The results show germinal centers have remarkable ability to select antibody producing cells along novel hypermutation trajectories, transmuting an antibody with no capacity to differentiate foreign from self into highly foreign-specific antibody derivatives, exploiting conformational flexibility in antigen and antibody. These findings address a central issue for developing vaccines against HIV and other chronic infections and represent a prime example of stepwise, evolutionary adaptation of protein–protein interfaces.

14 July 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
ACAdrian Chye
Adrian Chye
IAIndia Allen
India Allen
MBMegan Barnet
Megan Barnet
DBDeborah L. Burnett
Deborah L. Burnett
Blockade of immune checkpoints transformed the paradigm of systemic cancer therapy, enabling substitution of a cytotoxic chemotherapy backbone to one of immunostimulation in many settings. Invigorating host immune cells against tumor neo-antigens, however, can induce severe autoimmune toxicity which in many cases requires ongoing management. Many immune-related adverse events (irAEs) are clinically and pathologically indistinguishable from inborn errors of immunity arising from genetic polymorphisms of immune checkpoint genes, suggesting a possible shared driver for both conditions. Many endocrine irAEs, for example, have analogous primary genetic conditions with varied penetrance and severity despite consistent genetic change. This is akin to onset of irAEs in response to immune checkpoint inhibitors (ICIs), which vary in timing, severity and nature despite a consistent drug target. Host contribution to ICI response and irAEs, particularly those of endocrine origin, such as thyroiditis, hypophysitis, adrenalitis and diabetes mellitus, remains poorly defined. Improved understanding of host factors contributing to ICI outcomes is essential for tailoring care to an individual’s unique genetic predisposition to response and toxicity, and are discussed in detail in this review.